§ 81.21 - Cancers requiring the use of NIOSH-IREP.

Latest version.

§ 81.21 Cancers requiring the use of NIOSH-IREP.
(a) DOL will calculate probability of causation for all cancers , except chronic lymphocytic leukemia as provided under § 81.30, using NIOSH-IREP.
(b) Carcinoma in situ (ICD-9 10-CM codes 230D00-234D09), neoplasms of uncertain behavior (ICD-9 10-CM codes 235D37-238D44 and D48), and neoplasms of unspecified nature (ICD-9 10-CM code 239D49) are assumed to be malignant, for purposes of estimating probability of causation.
(c) All secondary and unspecified cancers of the lymph node (ICD-9 code 19610-CM codes C77 and C7B.01) shall be considered secondary cancers (cancers resulting from metastasis of cancer from a primary site). For claims identifying cancers of the lymph node, Table 1 in § 81.23(a) provides guidance for assigning a primary site and calculating probability of causation using NIOSH-IREP.
[84 FR 37590, Aug. 1, 2019]

                    
                        var val = document.getElementById('citecontent').innerHTML;
                        art.dialog.defaults.title = window.location.href;
                        art.dialog.data('cite', val);
                        art.dialog.data('homeDemoPath', '/Scripts/plus/artDialog/');
                        art.dialog.open('/Scripts/plus/artDialog/citeiframe.html');

§ 81.21 - Cancers requiring the use of NIOSH-IREP.

§ 81.21 Cancers requiring the use of NIOSH-IREP.